EnGeneIC Overview

  • Founded
  • 2001
Founded
  • Status
  • Private
  • Employees
  • 35
Employees
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $150K
Latest Deal Amount
  • Investors
  • 5

EnGeneIC General Information

Description

Developer of a cyto-immunotherapy technology created to target delivery of chemotherapeutics and functional nucleic acids in cancer. The company's technology utilizes antibody-targeted, bacterially derived, non-living nanocells to release high concentrations of chemotherapeutic agents, molecularly targeted drugs, and RNA-interference molecules directly into targeted tumor cells, enabling current cancer treatments to be more potent and far less toxic, while also offering a potential new means for treating drug-resistant cancers.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
  • 2/25 Sirius Road
  • Entrance off Mars Road, Lane Cove West
  • Sydney, New South Wales 2066
  • Australia
+61 (02) 0000 0000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

EnGeneIC Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 13-Apr-2017 $150K 000.00 Completed Clinical Trials - Phase 1
3. Later Stage VC 24-Jul-2015 00.00 000.00 Completed Clinical Trials - Phase 1
2. Later Stage VC (Series B) 06-Jan-2015 $10M $11M Completed Clinical Trials - Phase 1
1. Angel (individual) 27-Jul-2011 $1.02M $1.02M Completed Startup
To view EnGeneIC’s complete valuation and funding history, request access »

EnGeneIC Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a cyto-immunotherapy technology created to target delivery of chemotherapeutics and functional nucleic acid
Drug Discovery
Sydney, Australia
35 As of 2020
000.00
0000000000 0 000.00

000000

ididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco
0000 000000000
Cambridge, MA
00 As of 0000
00000
00000000 00000

00000000

em ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et
0000 000000000
New York, NY
000 As of 0000
00000
000000 - 000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

EnGeneIC Competitors (26)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Codiak Venture Capital-Backed Cambridge, MA 00 00000 00000000 00000
000000000(00000000 Formerly VC-backed New York, NY 000 00000 000000 - 000 00000
000 (0000000000000 Formerly VC-backed San Francisco, CA 000 00000 00000000 00000
000000 00000000000 Formerly VC-backed Boston, MA 0000 00.000 0000 00.000
000000 00000000 Formerly VC-backed Boulder, CO 000 00000 000000 - 000 00000
You’re viewing 5 of 26 competitors. Get the full list »

EnGeneIC Executive Team (7)

Name Title Board Seat Contact Info
Himanshu Brahmbhatt Ph.D Co-Founder, Co-Chief Executive Officer & Board Member
Jennifer MacDiarmid Co-Founder, Co-Chief Executive Officer & Board Member
William Harris Chief Financial Officer
David Seaton Chief Operating Officer
Nick Rengel JD Senior Vice President, Business Development
You’re viewing 5 of 7 executive team members. Get the full list »

EnGeneIC Board Members (12)

Name Representing Role Since
Edward Miller MD Self Board Member 000 0000
Himanshu Brahmbhatt Ph.D EnGeneIC Co-Founder, Co-Chief Executive Officer & Board Member 000 0000
Jennifer MacDiarmid EnGeneIC Co-Founder, Co-Chief Executive Officer & Board Member 000 0000
Richard Woods Self Board Member 000 0000
Yvonne Perlberg EnGeneIC Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

EnGeneIC Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

EnGeneIC Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
CHAMP Ventures PE/Buyout Minority 000 0000 000000 0
Foley Ventures Venture Capital Minority 000 0000 000000 0
Momentum Investment Group Venture Capital Minority 000 0000 000000 0
Shepherd Kaplan Krochuk Hedge Fund Minority 000 0000 000000 0
Kevin D'Silva Angel (individual) Minority 000 0000 000000 0
To view EnGeneIC’s complete investors history, request access »